- Home
- CANF vs MTR Comparison
CANF vs MTR Comparison
Compare CANF & MTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MTR
- Stock Information
- Founded
- CANF 1994
- MTR 1979
- Country
- CANF Israel
- MTR United States
- Employees
- CANF N/A
- MTR N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MTR Oil & Gas Production
- Sector
- CANF Health Care
- MTR Energy
- Exchange
- CANF Nasdaq
- MTR Nasdaq
- Market Cap
- CANF 13.5M
- MTR 10.9M
- IPO Year
- CANF N/A
- MTR N/A
- Fundamental
- Price
- CANF $0.66
- MTR $5.84
- Analyst Decision
- CANF Strong Buy
- MTR
- Analyst Count
- CANF 2
- MTR 0
- Target Price
- CANF $14.00
- MTR N/A
- AVG Volume (30 Days)
- CANF 314.0K
- MTR 7.2K
- Earning Date
- CANF 08-29-2025
- MTR 01-01-0001
- Dividend Yield
- CANF N/A
- MTR 3.61%
- EPS Growth
- CANF N/A
- MTR N/A
- EPS
- CANF N/A
- MTR 0.23
- Revenue
- CANF $674,000.00
- MTR $668,826.00
- Revenue This Year
- CANF $461.72
- MTR N/A
- Revenue Next Year
- CANF N/A
- MTR N/A
- P/E Ratio
- CANF N/A
- MTR $25.79
- Revenue Growth
- CANF N/A
- MTR N/A
- 52 Week Low
- CANF $0.63
- MTR $4.70
- 52 Week High
- CANF $3.24
- MTR $10.42
- Technical
- Relative Strength Index (RSI)
- CANF 12.02
- MTR 54.73
- Support Level
- CANF $1.00
- MTR $5.47
- Resistance Level
- CANF $1.05
- MTR $5.98
- Average True Range (ATR)
- CANF 0.05
- MTR 0.21
- MACD
- CANF -0.04
- MTR 0.02
- Stochastic Oscillator
- CANF 5.86
- MTR 81.58
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.